SCHEMBL4919280

SCHEMBL4919280

CC(C)(C)C(=O)Nc1cccc2sc(Nc3ccccc3)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
TP53 P04637 4/20 0.48
NPC1 O15118 8/20 0.48
RAB9A P51151 8/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
HPGD P15428 3/20 0.48
LMNA P02545 2/20 0.48
CDK5 Q00535 1/20 0.48
CDK5R1 Q15078 1/20 0.48
RET P07949 1/20 0.46
FLT1 P17948 1/20 0.46
KDR P35968 1/20 0.46
MAPK14 Q16539 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
ALDH1A1 P00352 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916241 0.86 DYRK1A (0.56) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL4916415 0.86 RET (0.47) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL4915377 0.84 MAPT (0.59) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL4908655 0.83 GAA (0.50) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL4908696 0.82 NPC1 (0.52) MAPTNPC1RAB9ASMN1; SMN2CDK5
SCHEMBL9718841 0.80 NPC1 (0.60) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL4919944 0.80 NPC1 (0.51) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL4913870 0.80 TRPV1 (0.47) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL4915044 0.80 SMN1; SMN2 (0.55) MAPTNPC1RAB9ASMN1; SMN2HPGD
SCHEMBL4916854 0.79 LCK (0.54) MAPTNPC1RAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US claimed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
WO-2007121154-A2 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 WO disclosed
WO-2007121154-A2 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K2 MAPT 1314/4885TP53 1607/4885NPC1 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.